Prostate cancer, version 1.2014.

Journal Article (Journal Article)

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

Full Text

Duke Authors

Cited Authors

  • Mohler, JL; Kantoff, PW; Armstrong, AJ; Bahnson, RR; Cohen, M; D'Amico, AV; Eastham, JA; Enke, CA; Farrington, TA; Higano, CS; Horwitz, EM; Kawachi, MH; Kuettel, M; Lee, RJ; Macvicar, GR; Malcolm, AW; Miller, D; Plimack, ER; Pow-Sang, JM; Richey, S; Roach, M; Rohren, E; Rosenfeld, S; Small, EJ; Srinivas, S; Stein, C; Strope, SA; Tward, J; Walsh, PC; Shead, DA; Ho, M; National comprehensive cancer network,

Published Date

  • December 1, 2013

Published In

Volume / Issue

  • 11 / 12

Start / End Page

  • 1471 - 1479

PubMed ID

  • 24335682

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2013.0174


  • eng

Conference Location

  • United States